Hyperlipoproteinemias
6
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Mipomersen Sodium
Research Leaders
8 sponsors active, led by Kastle Therapeutics, LLC
Related Conditions
Often studied with 19 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
50%
3 trials in Phase 3/4
83%
5 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (6)
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Evaluating the Impact of B Vitamin Supplementation (Soloways™) on Homocysteine and LDL-C Levels in Patients With MTHFR, MTR, and MTRR Polymorphisms.
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Research Network
Common Treatments
- Mipomersen Sodium2
- Obicetrapib1
- Mipomersen1
- Vupanorsen1
- Vitamin B1
Active Sponsors
- Kastle Therapeutics, LLC3
- Ionis Pharmaceuticals, Inc.3
- Center of New Medical Technologies1
- The TIMI Study Group1
- Triangel Scientific1
Top Investigators
NewAmsterdam Pharma
Related Conditions
- Dyslipidemias5
- Hypercholesterolemia4
- Lipid Metabolism Inborn Errors4
- Hyperlipidemias4
- Genetic Diseases Inborn3